Join to View Full Profile
200 1st St SwRochester, MN 55905
Phone+1 507-284-2511
Dr. Sarkaria is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
University of Wisconsin Hospitals and ClinicsResidency, Radiation Oncology, 1991 - 1995
University of HawaiiInternship, Transitional Year, 1990 - 1991
David Geffen School of Medicine at UCLAClass of 1990
Certifications & Licensure
MN State Medical License 1997 - 2025
WI State Medical License 1991 - 2025
HI State Medical License 1990 - 1992
American Board of Radiology Radiation Oncology
Clinical Trials
- Bortezomib, Paclitaxel, Carboplatin and Radiation Therapy for Non-Small Cell Lung Cancer Start of enrollment: 2004 Sep 01
- Temsirolimus, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme Start of enrollment: 2006 May 01
- Everolimus, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Start of enrollment: 2009 Mar 01
- Join now to see all
Publications & Presentations
PubMed
- The impact of therapeutic radiation on drug distribution across the blood-brain barrier in normal mouse brain and orthotopic GBM tumors.Wenjuan Zhang, Michael P Grams, Rajneet K Oberoi, Ju-Hee Oh, Paul A Decker
Neuro-Oncology. 2025-03-31 - Minibeam Radiation Therapy Valley Dose Determines Tolerance to Acute and Late Effects in the Mouse Oral Cavity.Darwin A Garcia, Jennifer M Fazzari, Ruslan Hlushchuk, Oleksiy-Zakhar Khoma, Katrina K Bakken
International Journal of Radiation Oncology, Biology, Physics. 2025-03-15 - Veliparib Plus Temozolomide for MGMT-Methylated Glioblastoma-Reply.Jann N Sarkaria, Sani H Kizilbash, Caterina Giannini
JAMA Oncology. 2025-03-13
Journal Articles
- Integrated Mapping of Pharmacokinetics and Pharmacodynamics in a Patient-Derived Xenograft Model of GlioblastomaJann Sarkaria, MD, Nature
- A Novel Enhancer Regulates MGMT Expression and Promotes Temozolomide Resistance in GlioblastomaIan F Parney, Fredric B Meyer, Caterina Giannini, Jann N Sarkaria, Nature
Press Mentions
- Dominant-Negative ATF5 Rapidly Depletes Survivin in Tumor CellsSeptember 24th, 2020
Why Is Glioblastoma Such a Tough Nut to Crack?December 24th, 2019
Mimicking Cancer, One Model at a TimeNovember 2nd, 2019- Join now to see all
Grant Support
- Maximizing the efficacy of MDM2 inhibitor therapy for MDM2-amplified glioblastomaMAYO CLINIC ROCHESTER2024–2029
- Development of the brain penetrant ATM inhibitor WSD0628 in combination with radiation for recurrent high grade gliomaMAYO CLINIC ROCHESTER2023–2028
- Center of Innovation for Brain Tumor TherapeuticsMAYO CLINIC ROCHESTER2021–2026
- In vivo SELEX strategies to identify potent aptamer-drug conjugates for glioblastomaMAYO CLINIC ROCHESTER2023–2025
- Protocal Specific Research SupportNational Cancer Institute2009–2012
- Overcoming Therapy Resistance In GBMNational Cancer Institute2009–2012
- Epigenetic Regulation Of Temozolomide Responsiveness In GlioblastomaNational Cancer Institute2008–2012
- Early Prediction Of Response To Combined Modality Therapy By Functional ImagingNational Cancer Institute2007–2008
- Optimizing EGFR Inhibitor-Based Therapies In GBMNational Cancer Institute2004–2008
- Daily Oral Sirolimus (RAPA) And Cisplatin With Concurrent Thoracic RadiationNational Center For Research Resources2005
- FLT PET Imaging For Evaluating Molecular TherapeuticsNational Cancer Institute2004–2005
- ATM Kinase As A Novel Target For Radiosensitizing AgentsNational Cancer Institute1999–2003
- P53 Induction As A Predictor Of Radiation ComplicationsNational Cancer Institute1996–1998
- P53 Induction As A Predictor Of Radiation ComplicationsNational Cancer Institute1996
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
